PharmiWeb.com - Global Pharma News & Resources
15-Nov-2018

Human Vaccines 2016-2024 - Global Strategic Business Report 2018: Emerging Nations Offer Huge Opportunities for Pediatric Vaccine Manufacturers - ResearchAndMarkets.com

The "Human Vaccines - Global Strategic Business Reports" report has been added to ResearchAndMarkets.com's offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets.

This report analyzes the worldwide markets for Human Vaccines by the following Product Segments:
  • Pediatric Vaccines
  • Adult Vaccines

Company profiles are primarily based on public domain information including company URLs.

The report profiles 66 companies including many key and niche players such as:
  • ALK
  • Abell A/S (Denmark)
  • Altimmune, Inc. (US)
  • Bavarian Nordic A/S (Denmark)
  • BiondVax Pharmaceuticals Ltd. (Israel)
  • Bharat Biotech International Limited (India)
  • GlaxoSmithKline Plc. (UK)
  • Hualan Biological Engineering Inc. (China)
  • Janssen Pharmaceuticals, Inc. (US)
  • MedImmune (US)
  • Merck & Co., Inc. (US)
  • Pfizer Inc. (US)
  • Sanofi Pasteur SA (France)
  • Serum Institute of India Pvt. Ltd. (India)
  • Shanghai BravoBio Co., Ltd. (China)
  • Seqirus (UK)
  • SK Chemicals Co., Ltd. (Korea)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Zydus Cadila (India)

Key Topics Covered

1. MARKET OVERVIEW & OUTLOOK
  • Human Vaccines: A Prelude
  • Human Vaccines Market
  • A Snapshot
  • Market Dynamics
  • Growth Drivers in a Capsule
  • Developed World: The Key Markets
  • Emerging Markets: The Future Growth Area
  • Vaccine Pricing: The Developed
  • Developing Divide

2. MARKET TRENDS & ISSUES

  • Prophylactic Pediatric Vaccines
  • A Mature Market
  • Emerging Nations Offer Huge Opportunities for Pediatric Vaccine Manufacturers
  • Rising Incidence of Infectious Diseases to Fuel Growth of Anti-Infective Vaccines
  • Novel Vaccines against Emerging Infectious Diseases
  • Ongoing Developments for a Vaccine against Zika Virus
  • Sanofi's Dengue Vaccine First-to-Market
  • Pipeline & Marketed Dengue Vaccine: 2016
  • Computational Tools Come to Aid in Development of Ebola Vaccines
  • Vaccine for AIDS
  • Ongoing Research for HIV Vaccine & Commercial Pipeline
  • List of Clinical Trial (Phase II) AIDS Vaccines: 2015
  • Staggering Global Statistics of AIDS
  • Opportunity Indicator
  • Vaccination-Autism Link and Other Safety Concerns Thwarted
  • Threat of Pandemic Rejuvenates Vaccine Market
  • Influenza Vaccines on a Growing Spree
  • Influenza Vaccines on the Current Market: 2016
  • H1N1 Vaccines Hit the Market in August 2009
  • H1N1 Influenza Vaccines and Manufacturers
  • Influenza Market Faces Several Challenges
  • Rising Disease Incidence and Increasing Awareness Drive the Global Meningococcal Vaccines Market
  • Unmet Demand for TB Vaccine
  • Key TB Vaccine Candidates in the Pipeline: 2016
  • Need for a Human Vaccine for Leishmaniasis
  • Economic Factors Hamper Optimal Vaccine Development and Delivery
  • Increasing Need for Vaccine Promotion in the Developing Regions
  • Changing Vaccine Needs
  • Religious Concerns over Immunizing Young Girls against Human Papillomavirus
  • Changing Travel Patterns Increase Demand for Hepatitis B Vaccine
  • DNA Vaccines: Engineering Growth
  • Noninjectable Vaccines: Gain without Pain
  • Application of Botulinum Toxin as Delivery Mechanism for Oral Vaccines
  • Conjugate Vaccines: A Technological Innovation
  • Hib Vaccines on the Market: 2016
  • Growing Pricing Pressure
  • A Major Market Deterrent
  • Safety Issues Come to the Fore
  • BioWarfare: Threat Perception and Preparedness
  • Overview of Potential Bio-Terrorist Agents
  • Smallpox (Variola Major)
  • Anthrax (Bacillus Anthracis)
  • Plague (Yersinia Pestis)
  • Botulism (Clostridium Botulinum)
  • Tularemia (Francisella Tularensis)
  • Tackling Cold Chain Issues
  • Trade Statistics

3. COMPETITIVE LANDSCAPE

  • Pfizer Scores Big with Prevnar
  • Trumenba Shows Promise in Phase III Clinical Trials
  • GSK Takes Big Leap into the Meningococcal Vaccine Market
  • Acquired Products Strengthen GSK's Vaccines Sales
  • The Potential for MenABCWY Vaccine
  • Sanofi Works on Production Issues to Boost Sales
  • New Vaccines to Enhance Prospects for Sanofi
  • Sanofi's Human Vaccine R&D Pipeline
  • Weaker Sales Drive Merck and Sanofi's European JV Split
  • Serum Institute to Stir Competitive Landscape in the HPV Vaccine Market

4. PRODUCT OVERVIEW

5. CLINICAL TRIALS IN THE VACCINES MARKET
  • Inovio and GeneOne to Initiate Phase 1 Human Trial for Zika DNA Vaccine
  • Takeda Begins Phase2b Trial for World's First Norovirus Vaccine
  • Bavarian Nordic Announces Positive Results from Phase 1 Trial of RSV Vaccine
  • Investigational Vaccine for P.vivax Malaria Enters Human Trials
  • Valneva Reports Postive Phase 2 Results for Vaccine Candidate against C.difficile
  • Novavax Announces Positive Phase 2 Clinical Trial Results for RSV-F Protein Vaccine
  • Vical Reports Postive Preclinical Data for CyMVectin CMV vaccine
  • Profectus BioSciences Receives HHS Contract to Accelerate Ebola Vaccine Candidate into Clinical Studies
  • Inovio and GeneOne to Advance Ebola Vaccine into Phase 1 Trial

6. PRODUCT LAUNCHES/APPROVALS

  • FDA Approves 2016/17 Formulation of Protein Sciences Corporation's Flublok
  • Sanofi's Dengue Vaccine Approved in Costa Rica
  • GSK Supplies Flu Vaccines based on Valneva's EB66 Cell Line
  • FDA Approves Seqirus' FLUCELVAX QUADRIVALENT Influenza Vaccine
  • China Launches HFMD Vaccine
  • Bharat Biotech Introduces ZIKAVAC Vaccine for Zika Infection
  • Sanofi Pasteur Launches Vaccine R&D Project for Zika Virus Infection
  • WHO Accepts Merck's Investigational Ebola Vaccine Application for Review
  • Sanofi's Dengvaxia Receives Marketing Authorization in Mexico
  • SK Chemicals Launches Influenza Vaccine SKYCellflu
  • Sanofi Pasteur Ships First Doses of Fluzone for the US Market
  • Bharat Biotech Launches Made-in-India ROTAVAC Vaccine

7. RECENT INDUSTRY ACTIVITY

  • WHO Prequalifies Four-dose, Multi-dose Vial Presentation of Pfizer's Prevnar 13
  • Sanofi Pasteur Begins Vaccine Manufacturing at Its Affiliate Shantha Biotechnics' Facility
  • Bavarian Nordic Announces IMVAMUNE Supply Contract with US Government
  • Stellar Biotechnologies and Neovacs Form JV to Develop Conjugated Vaccines
  • WHO Recommends Sanofi's Dengvaxia in Nations with Widespread Dengue
  • Kaketsuken to Sell Vaccines Business to Astellas
  • Sanofi and Merck End Joint Venture on Vaccines
  • GeoVax Labs Collaborates with USAMRID for Hemorrhagic Fever Vaccine
  • Bavarian Nordic Collaborates with Evaxion for Vaccine against MRSA
  • Bavarian Nordic Enters into License Agreement with Janssen
  • CSL Rebrands Influenza Vaccines Business as Seqirus
  • MedImmune Joins Human Vaccines Project for Cancer and Infectious Disease Vaccine R&D
  • GlaxoSmithKline Acquires Novartis' Vaccines Business
  • Vaxin Changes Name to Altimmune
  • Takeda Expands Commercialization Agreement with Nanotherapeutics
  • MedImmune Enters Into License Agreement with Inovio Pharmaceuticals
  • CSL Completes Acquisition of Novartis' Influenza Vaccines Business
  • Pfizer to Acquire Meningitis Vaccines from GSK
  • Pfizer Stops Prevnar Vaccine Sales in China After Government Fails to Renew License

8. FOCUS ON SELECT PLAYERS

9. GLOBAL MARKET PERSPECTIVE

Total Companies Profiled: 63 (including Divisions/Subsidiaries 72) The United States (22) Canada (1) Japan (5) Europe (14)
  • France (3)
  • Germany (2)
  • The United Kingdom (2)
  • Spain (1)
  • Rest of Europe (6)

Asia-Pacific (Excluding Japan) (28)

Latin America (1) Middle East (1)

For more information about this report visit https://www.researchandmarkets.com/research/hcpmgn/human_vaccines?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181115005666/en/

Editor Details

Last Updated: 15-Nov-2018